Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96

HIV Clinical Trials

Volumn 12, Issue 6, 2011, Pages 313-322

  Fourie, Jan ^a   Flamm, Jason ^b   Rodriguez French, Amalia ^c   Kilby, Don ^d   Domingo, Pere ^e   Lazzarin, Adriano ^f   Ballesteros, Juan ^g   Sosa, Nestor ^h   Van De Casteele, Tom ⁱ   Demasi, Ralph ^j   Spinosa Guzman, Sabrina ⁱ   Lavreys, Ludo ⁱ  

^a Dr J Fourie Medical Practice   (South Africa)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c Santo Tomas Hospital   (Panama)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g HOSPITAL DEL SALVADOR   (Chile)

^h Medical and Research Center   (Panama)

ⁱ TIBOTEC BVBA   (Belgium)

^j Tibotec Inc   (United States)

more..

Author keywords

darunavir; efficacy; HIV; safety; treatment na ve

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; ASTHENIA; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLATULENCE; FOLLOW UP; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; INCIDENCE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; PRURITUS; RACE DIFFERENCE; STEVENS JOHNSON SYNDROME; VOMITING;

ADULT; AGING; ANTI-HIV AGENTS; CONTINENTAL POPULATION GROUPS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RITONAVIR; RNA, VIRAL; SEX CHARACTERISTICS; SULFONAMIDES;

EID: 84255200717     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1206-313     Document Type: Article

References (28)

1. Clumeck N, Pozniak A, Raffi F, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9: 65-71. (Pubitemid 351228129)
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2009. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161.http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed December 3, 2010.
3. Hammer SM, Eron JJ Jr, Reiss P, et al. Treatment for Adult HIV infection. 2008 recommendations of the International AIDS Society-USA Panel. JAMA. 2008;300:555-570
4. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and effi -cacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796-806.
5. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48. AIDS. 2008;22:1389-1397.
6. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients: 96-week analysis of ARTEMIS. AIDS. 2009;23:1679-1688.
7. Brañas F, Berenguer J, Sánchez-Conde M, et al. The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy. Am J Med. 2008;121:820-824.
8. Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfanavir, and lamivudine/stavudine/ nefanavir on lipids, metabolic parameters and efficacy in antiretroviral- naïve patients: effect of sex and ethnicity. HIV Med. 2006;7:85-98.
9. Tedaldi EM, Abalson J, Thomas AJ, et al. Ethnicity, race and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST study). J Aquir Immune Defic Syndr. 2008;47:441-448. (Pubitemid 351366961)
10. Bica I, McGovern B, Dahr R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32: 492-497. (Pubitemid 32173638)
11. Lohse N, Hansen AB, Gerstoft J, et al. Improved survival in HIV-infected persons: consequences and perspectives. J Antimicrob Chemother. 2007;60:461-463. (Pubitemid 47303950)
12. Martín-Carbonero L, Soriano V, Valencia E, et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses. 2001;17:1467-1471. (Pubitemid 33116749)
13. Andrade-Villanueva J, Herrera G, Chiliade P, et al. ARTEMIS: Week 48 safety and efficacy of darunavir/r by gender, age and race. In: Program and abstracts of the 17th International AIDS Conference; 2008. [Abstract TUPE0064]
14. Prezista (darunavir). Full US prescribing information. Tibotec, Inc. 2009. http://www.prezista.com/prezista/documents/us-package-insert.pdf. Accessed December, 3 2010.
15. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. AIDS Clinical Trials Group Network. December 2004. https://actgnetwork.org/science-mission/guidelines/antiretoviral-treatment. Accessed December 3, 2010.
16. AIDS epidemic update: December 2006. UNAIDS (Joint United Nations Program on HIV/AIDS). December 2006.http://www.unaids.org/en/KnowledgeCentre/HIVData/ EpiUpdate/EpiUpdArchive/2006/Default.asp. Accessed December 3, 2010.
17. Greenbaum AH, Wilson LE, Keruly JC, et al. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS. 2008;22:2331-2339.
18. Hartzell JD, Spooner K, Howard R, et al. Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Aquir Immune Defic Syndr. 2007;44:411-416. (Pubitemid 46555375)
19. US prescribing information. Invirase (saquinavir mesylate). http://www.rocheusa.com/products/invirase. AccessedDecember 3, 2010.
20. Smith KY, Kumar PN, Patel P, et al. Differences in virologic response among African-Americans and Females regardless of therapy in the HEAT study. In: Program and abstracts of the 5th Conference of HIV Pathogenesis, Treatment and Prevention; 2009. [Abstract MOPE033]
21. Jang Y-R, Zhou J, Chuang S-Y, et al. Impact of HBV and HCV coinfection on the outcomes of antiretroviral treatment (ART) and disease progression in HIV-infected patients in Taiwan. In: Program and abstracts of the 5th Conference of HIV Pathogenesis, Treatment and Prevention; 2009. [Abstract WEPEB224]
22. Gulick R, Ribaudao H, Shikuma C, et al. Zidovudine/lamivudine/abacavir vs zidovudine/lamivudine + efavirenz vs zidovudin/lamivudine/abacavir + efavirenz for initial HIV therapy. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005. [Abstract H-416a]
23. da Silva B, King M, Cernohous P, et al. Lopinavir/ritonavir (LPV/r) safety, tolerability and efficacy in HIV patients coinfected with hepatitis C and/or B: review of clinical trials. In: Program and abstracts of the 15th International AIDS Conference; 2004. [Abstract MoPeB3281]
24. Dieterich D, Fischl M, Speulveda G. The safety/efficacy of protease inhibitors in hepatitis C (HCV) coinfected patients. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003. [Abstract H-831]
25. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis. 2001;32: 124-129. (Pubitemid 32150957)
26. Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS. 2008;22:540-541. (Pubitemid 351317299)
27. Dore G. Antiretroviral therapy-related hepatotoxicity: predictors and clinical management. J HIV Ther. 2003;8: 96-100.
28. SulkowskiM S, Mehta SH, Chaisson RE, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. 2004;18:2277-2284. (Pubitemid 39620220)